Vikas Dandekar is an Editor - Pharma & Healthcare at ET Prime. With over two decades of experience tracking the Indian pharmaceutical industry, he has reported extensively on topics such as digital health, consumer health, and the complexities of drug pricing and healthcare costs. Vikas has been featured in The Economic Times, where his insights on the evolving pharma landscape and healthcare technology continue to resonate.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
India (National)
Not enough data
Vikas Dandekar's coverage is heavily focused on healthcare, pharmaceuticals, and health-related topics in India with a specific emphasis on Mumbai. It seems he would be most interested in expert commentary from professionals within the healthcare and pharmaceutical industries regarding prevailing issues such as diabetes management, heart ailments, medical research breakthroughs, and regulatory changes.
If you have expertise or insights related to these areas or can provide analysis of government announcements impacting the healthcare sector in India (especially Mumbai), your pitch may resonate well with Vikas. Additionally, if you represent an organization making significant contributions to this industry locally or nationally, it could also capture his interest.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Vikas Dandekar, Rica Bhattacharyya
Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant global product filings over the next three years. Cipla will also expand its presence in North America and Europe. Innovation is expected to contribute a meaningful portion of revenues in the coming decade.
By: Rica Bhattacharyya, Vikas Dandekar
Wockhardts newly approved antibiotic Zaynich has the potential to transform the treatment of drug-resistant infections, according to Mahesh Patel, the scientist behind the drug. Approved by the US FDA for complicated urinary tract infections, Zaynich combines cefepime and zidebactam, using a novel “beta-lactam enhancer” mechanism that blocks two key steps in bacterial cell-wall synthesis, helping it overcome virtually all known resistance mechanisms.
By: Vikas Dandekar, Rica Bhattacharyya
It targets superbugs that resist current treatments. Zaynich offers a powerful synergy to overcome resistance. The drug has a significant market opportunity. Wockhardt anticipates market exclusivity until around 2038.
By: Vikas Dandekar, Rica Bhattacharyya
Wockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected to generate $1.5-2 billion in peak annual sales within 4-6 years. Wockhardt aims for a 20% share of the AMR market. The company is also developing new antibiotics for its pipeline.
Wockhardt Hospitals has received US approval for Zaynich, an innovative antibiotic expected to achieve peak sales of $1.5-2 billion annually in the next 4-6 years. CEO Habil Khorakiwala outlines the company's strategy and market projections.
By: Vikas Dandekar, Teena Thacker
India's drug pricing authority may soon approve a price hike for vital platinum-based cancer medicines. These drugs, including carboplatin and cisplatin, are crucial for treating various cancers. The National Pharmaceutical Pricing Authority met with drug makers and hospital representatives to discuss the issue. Rising raw material costs have put pressure on production.
By: Vikas Dandekar, Teena Thacker
India's government is taking emergency steps to ensure cancer patients get vital drugs. Cisplatin and carboplatin, crucial chemotherapy agents, faced shortages due to rising raw material costs. The government may allow significant price increases to boost production. This move aims to prevent treatment disruptions for thousands of patients across the nation. Revised prices are expected soon.
By: Teena Thacker, Vikas Dandekar
India's drug pricing authority has approved a 50% price hike for essential anti-cancer drugs carboplatin and cisplatin. This decision follows pleas from manufacturers citing soaring platinum costs. Anti-tetanus immunoglobulin drug prices also see an increase. The National Pharmaceutical Pricing Authority invoked special powers to ensure these life-saving medicines remain accessible to the public.
By: Vikas Dandekar, Rica Bhattacharyya
With an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The company underscores the importance of collaboration to tackle obstacles like high costs and inadequate infrastructure.
By: Arijit Barman, Vikas Dandekar
A gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Since the NGS test can be beyond the reach of many, a unique collaboration called LuNGS Alliance is making it free for lung cancer patients in India, offering a glimpse of how medical breakthroughs can be made accessible and affordable.
